Search Results

NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company developing high-quality biosimilar products, today disclosed two additional biosimilars in active development. The products are biosimilar candidates referencing Opdivo ® (nivolumab) and Keytruda ® (pembrolizumab). These biosimilars reference two antibody products that bl

NeuClone Pharmaceuticals Ltd (NeuClone) today announced its biosimilar candidate of Stelara ® (ustekinumab), NeuLara, has successfully met all primary and secondary endpoints in a Phase I clinical trial. This includes all pre-specified criteria demonstrating the clinical pharmacokinetic (PK) similarity of NeuLara, compared to US-

NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced successful recruitment and dosing of all subjects in the Phase I clinical trial for its Stelara® (ustekinumab) biosimilar candidate, NeuLara.

NeuClone Pharmaceuticals Ltd announced successful completion of monitoring visits and blood sampling for subjects in the Phase I clinical trial for its Stelara® biosimilar candidate, NeuLara.

NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced that NeuCeptin, a biosimilar candidate of Herceptin® (trastuzumab), has successfully met all primary and secondary endpoints in a Phase I clinical trial.

NeuClone, a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced it has commenced dosing of Stelara® (ustekinumab) biosimilar candidate, NeuLara, in a Phase I clinical trial.

NeuClone Pharmaceuticals Ltd. announced it will initiate the Phase I clinical trial of its Stelara® biosimilar in the second half of 2019.

Biopharmaceutical company NeuClone has announced positive preclinical results of its biosimilar to Johnson & Johnson’s Stelara®, including 3-dimensional (3-D) structure confirmation through X-ray crystallography analysis.

NeuClone Ltd, a biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced it has commenced first-in-human dosing of its Herceptin® (trastuzumab) biosimilar candidate, in a Phase I clinical trial.

NeuClone Pty. Ltd. today disclosed the fifth biosimilar candidate being developed in its pipeline of mAb products.